# Exhibit Review — Gemini 3 Flash (Round 1)

**Role:** Visual exhibit advisor
**Model:** gemini-3-flash-preview (ai_studio)
**Paper:** paper.pdf
**Timestamp:** 2026-03-05T17:19:26.587809
**Route:** Direct Google API + PDF
**Tokens:** 17877 in / 1795 out
**Response SHA256:** 4a96985d19704bab

---

# Exhibit-by-Exhibit Review

## Main Text Exhibits

### Table 1: "Summary Statistics: Clinical Trial Activity by State-Quarter"
**Page:** 8
- **Formatting:** Clean and professional. Numbers are easy to read, but they are not decimal-aligned.
- **Clarity:** Excellent. The comparison between "Eventually Treated" and "Never Treated" immediately highlights the level differences mentioned in the text.
- **Storytelling:** Essential. It establishes the baseline differences and the scale of the data (e.g., enrollment in the tens of thousands).
- **Labeling:** Clear. The notes explain the sample and the "Never Treated" definition well.
- **Recommendation:** **REVISE**
  - Decimal-align the numbers in the first two columns to improve professional polish.
  - Add a "Total" column to provide a sense of the aggregate sample mean for each variable.

### Figure 1: "Dynamic Treatment Effects of Right-to-Try Laws on Clinical Trials"
**Page:** 14
- **Formatting:** Standard three-panel layout. Font sizes are legible. The use of a dashed vertical line for treatment and a horizontal line for zero is standard for top journals.
- **Clarity:** High. Shaded 95% CIs are translucent enough to see the point estimates.
- **Storytelling:** This is the "money" figure of the paper. It visually confirms the lack of pre-trends and the null post-treatment effect across the three primary outcomes.
- **Labeling:** Good. The Y-axis specifies "log points," which is crucial for interpreting the coefficients.
- **Recommendation:** **KEEP AS-IS**

### Figure 2: "Staggered Adoption of State Right-to-Try Laws"
**Page:** 15
- **Formatting:** High-quality map. The color palette is distinguishable.
- **Clarity:** High. It quickly conveys the geographic dispersion of the policy.
- **Storytelling:** Strong. It supports the argument that adoption wasn't limited to a single region, which helps the identification strategy's credibility.
- **Labeling:** The legend is clear.
- **Recommendation:** **KEEP AS-IS**

### Figure 3: "Clinical Trial Activity by Right-to-Try Treatment Status"
**Page:** 16
- **Formatting:** Professional. No unnecessary gridlines. 
- **Clarity:** Good. The raw trends are clear.
- **Storytelling:** Useful for showing the "raw" data before the DiD transformation, which builds confidence in the results.
- **Labeling:** The callout for "First RTT law (CO, May 2014)" is a nice touch that adds context.
- **Recommendation:** **KEEP AS-IS**

### Figure 4: "Bacon Decomposition of TWFE Estimator"
**Page:** 18
- **Formatting:** Standard scatter plot for this diagnostic.
- **Clarity:** A bit cluttered on the left-hand side where weights are low.
- **Storytelling:** Important for modern DiD papers to address the "bad weights" problem in TWFE. It justifies the use of Callaway-Sant’Anna.
- **Labeling:** Legend and axes are appropriate.
- **Recommendation:** **KEEP AS-IS** (or move to Appendix if space is tight, though journals currently like seeing this).

### Table 2: "Effect of Right-to-Try Laws on Clinical Trial Activity"
**Page:** 12
- **Formatting:** Excellent. Use of Panel A and B is very effective.
- **Clarity:** High. It summarizes the main findings and placebos in one place.
- **Storytelling:** This is the core results table. It clearly presents the "Precise Null" message.
- **Labeling:** Significance stars are used and defined. Standard errors are in parentheses.
- **Recommendation:** **KEEP AS-IS**

### Table 3: "Robustness Checks: Trial Sites (Phase II/III)"
**Page:** 19
- **Formatting:** Consistent with other tables.
- **Clarity:** Very clear. The "Additional diagnostics" section at the bottom is a clever way to include RI and MDE.
- **Storytelling:** Shows the result is not driven by specific large states or specification choices.
- **Labeling:** Clear notes.
- **Recommendation:** **KEEP AS-IS**

### Figure 5: "Leave-One-State-Out: Sensitivity to Major Biotech Hubs"
**Page:** 20
- **Formatting:** Very clean horizontal forest plot.
- **Clarity:** The blue vertical line for the full sample estimate makes comparison easy.
- **Storytelling:** Effectively visualizes the stability of the coefficient.
- **Labeling:** Clear.
- **Recommendation:** **KEEP AS-IS**

### Figure 6: "Randomization Inference: Distribution of Placebo Treatment Effects"
**Page:** 21
- **Formatting:** Professional histogram. 
- **Clarity:** The red lines for "Observed" and its mirror image are helpful.
- **Storytelling:** Adds another layer of robustness to the null.
- **Labeling:** P-value is clearly displayed.
- **Recommendation:** **KEEP AS-IS**

### Figure 7: "Placebo Tests: Outcomes Unaffected by Right-to-Try Laws"
**Page:** 22
- **Formatting:** Matches Figure 1 for consistency.
- **Clarity:** High. 
- **Storytelling:** Parallel to Figure 1 but for placebos. This is very convincing.
- **Labeling:** Good.
- **Recommendation:** **KEEP AS-IS**

## Appendix Exhibits

### Table 4: "TWFE Results (Reference)"
**Page:** 32
- **Formatting:** Consistent with Table 2.
- **Clarity:** High.
- **Storytelling:** Necessary to show that the null isn't just an artifact of the CS estimator.
- **Labeling:** Properly cross-referenced to Table 2 in the notes.
- **Recommendation:** **KEEP AS-IS**

### Table 5: "Right-to-Try Law Adoption by Year"
**Page:** 32
- **Formatting:** Simple list format.
- **Clarity:** High.
- **Storytelling:** Essential reference for anyone wanting to replicate the timing.
- **Labeling:** Clear.
- **Recommendation:** **KEEP AS-IS**

---

## Overall Assessment

- **Exhibit count:** 3 main tables, 7 main figures, 2 appendix tables, 0 appendix figures.
- **General quality:** Extremely high. The paper follows modern "Best Practices" for empirical microeconomics (event studies, Bacon decomposition, randomization inference, and MDE analysis).
- **Strongest exhibits:** Figure 1 (Main Results Event Study) and Table 2 (Consolidated Results).
- **Weakest exhibits:** Table 1 (needs decimal alignment) and Figure 4 (Bacon plots are inherently a bit messy, but this one is standard).
- **Missing exhibits:** 
    - **Balance Table:** While the author discusses level differences, a formal balance table showing that pre-treatment *trends* (e.g., growth in trials from 2008-2012) are not correlated with adoption timing would be the "gold standard" for QJE/AER.
    - **Effectiveness Plot:** A figure showing the Rambachan-Roth sensitivity bounds mentioned on page 23 would be more impactful than a textual description.

**Top 3 improvements:**
1. **Decimal alignment:** Ensure all columns in Tables 1, 2, 3, and 4 are decimal-aligned to meet the highest aesthetic standards of top-tier journals.
2. **Visualize Rambachan-Roth:** Add a figure for the Rambachan-Roth sensitivity analysis. These "Honest DiD" plots are becoming expected in top journals to quantify how much of a trend violation would be needed to overturn the result.
3. **Consolidate Robustness:** Figure 5 and Table 3 have some overlap. Consider moving Figure 5 to the Appendix and keeping Table 3 in the main text to reduce the number of figures (7 figures is on the high side for some journals; 5 is often the sweet spot).